TCM
BMRN icon

Tuttle Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tuttle Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,883
Closed -$524K – 186
2020
Q3 		$524K Buy
+6,883
New +$696K 0.36% 68

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Tuttle Capital Management's BMRN Position: Q4 2020 in Review

Tuttle Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2020, closing a stake of 6,883 shares — an estimated $524K sold.

Tuttle Capital Management first reported a position in BMRN in Q3 2020 and held it in 1 quarter. The position peaked at $524K in Q3 2020. 537 funds tracked by Wall St. Rank hold BMRN as of Q4 2020.

  • Tuttle Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Tuttle Capital Management sold 6,883 BioMarin Pharmaceuticals shares in Q4 2020, an estimated $524K.
  • Tuttle Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Tuttle Capital Management's BioMarin Pharmaceuticals position peaked at $524K in Q3 2020.
  • 537 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2020.

Based on Tuttle Capital Management's 13F filing for Q4 2020, filed 20 Jan 2021.